26 results
424B3
SCLX
Scilex Holding Company
2 Apr 24
Prospectus supplement
5:20pm
Application (“NDA”). We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las … and secondary endpoints. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las
424B3
SCLX
Scilex Holding Company
2 Apr 24
Prospectus supplement
5:19pm
Application (“NDA”). We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las … and secondary endpoints. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las
POS AM
SCLX
Scilex Holding Company
27 Mar 24
Prospectus update (post-effective amendment)
5:30pm
Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.
Pursue clinical development of SP-103 for the first approved … Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.
The Phase 3 CLEAR trial summary results, which results reflect
POS AM
SCLX
Scilex Holding Company
27 Mar 24
Prospectus update (post-effective amendment)
5:29pm
trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.
Pursue clinical development … trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.
The Phase 3 CLEAR trial summary
424B3
iwx4b7g5gj 244
22 Nov 23
Prospectus supplement
5:07pm
8-K
EX-99.1
t9248j6fjdkhrdn
21 Jun 23
Regulation FD Disclosure
5:56pm
424B3
ka2ydwc
19 Apr 23
Prospectus supplement
4:41pm